Navigation Links
ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007
Date:3/31/2008

p>General and administrative 2,951 1,813 7,749 6,087

Total cost and expenses 5,744 4,835 17,020 17,029

Operating loss (5,037) (2,185) (15,692) (8,669)

Interest and other

income, net 63 159 381 548

Interest expense (450) (187) (1,515) (862)

Gain on extinguishment

of debt 16,127 - 16,127 219

Net income (loss) 10,703 (2,213) (699) (8,764)

Deemed dividend from

beneficial conversion

feature for Series F

redeemable convertible

preferred stock - - - (13,842)

Accretion of dividends

on preferred stock (441) - (1,167) (867)

Reversal of accretion

of dividends on

preferred stock not paid - - - 4,919

Net loss attributed to

common stockholders $10,262 $(2,213) $(1,866) $(18,554)

Net loss per share:

- Basic and diluted $3.94 $(0.24) $(0.72) $(3.16)

Shares used in computing

net loss per share:

- Basic and diluted 2,606,739 9,070,994 2,599,425 5,868,131

ImaRx Therapeutics, Inc.

Selected Balance Sheet Data (in thousands)

December 31 December 31

2006 2007

ASSETS

Current assets:

Cash and cash equivalents $4,256 $12,861

Restricted cash - 388

Accounts receivable, net 576 349

Inventory
'/>"/>

SOURCE ImaRx Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
2. ImaRx to Report Corporate Updates and 4Q07 Financial Results
3. ImaRx Reschedules Release of Corporate Updates and Fourth Quarter and Full Year 2007 Financial Results
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
6. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
7. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
8. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
9. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
10. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
11. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... -- The healthcare landscape is rapidly and radically changing. To ... host its 20 th Anniversary Medical Technologies 2015: ... 10, at the Hilton San Diego Resort and Spa in ... event is a platform for global medical devices, diagnostics, life ... how to succeed in an uncertain future. Participants ...
(Date:2/26/2015)... February 26, 2015 Already well respected ... line by expanding its Length Gauge offerings with new ... , Specifically, HEIDENHAIN’s pencil probe-style SPECTO length ... specification. Two new 1Vpp, 12mm stroke length variants ... applications. One is a variant with a weak spring, ...
(Date:2/26/2015)... February 26, 2015 According to a ... Biotechnology Market For Transgenic Crops (Corn, Soybean, Cotton and ... Analysis, Size, Share, Growth, Trends and Forecast, 2013 – ... 15,300 million in 2012 and is expected to reach ... of 9.5% from 2013 to 2019. , Demand ...
(Date:2/26/2015)... OAKS, Calif. , Feb. 26, 2015 ... achieved Gold Partner status in Oracle PartnerNetwork. In attaining ... for its commitment to establish Oracle-related knowledge in delivering ... the challenges of joint customers. Originally developed ... researchers to rapidly zoom in and out of massive ...
Breaking Biology Technology:Embrace the Future of Medical Technologies with Frost & Sullivan 2Embrace the Future of Medical Technologies with Frost & Sullivan 3Accuracy and Versatile Gauging Go Hand in Hand at HEIDENHAIN 2Global Agricultural Biotechnology Market is Expected to Reach USD 28,694.1 Million in 2019 : Transparency Market Research 2Global Agricultural Biotechnology Market is Expected to Reach USD 28,694.1 Million in 2019 : Transparency Market Research 3Ceres Becomes Oracle PartnerNetwork Gold Level Partner 2Ceres Becomes Oracle PartnerNetwork Gold Level Partner 3Ceres Becomes Oracle PartnerNetwork Gold Level Partner 4
... - Oncolytics Biotech Inc.,(TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the ... ended December 31, 2007., "2007 was our ... of the Company,s clinical trial program for REOLYSIN(R) ... being expanded and,initiated," said Dr. Brad Thompson, President ...
... March 6 VWR Funding, Inc., the,parent company of VWR International, LLC, a leading global ... and year-end financial results., Who: ... Jack L. Wyszomierski, Executive Vice-President & Chief ... Financial Officer, When: Wednesday, March 12, ...
... on Clinical Developments, MONTREAL, March 6 /PRNewswire-FirstCall/ - ... findings from the,third cohort in its Phase II trial ... the compiled data from a,total of 18 patients showed ... at weeks 4, 6 and 8, and of the ...
Cached Biology Technology:Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007 2Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007 3Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007 4Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007 5Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007 6Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007 7Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007 8Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007 9VWR Funding, Inc. to Hold Fourth Quarter and Year-End 2007 Financial Results Conference Call 2ProMetic reports continued positive data in PBI-1402 phase II trial in chemotherapy-induced anemia 2ProMetic reports continued positive data in PBI-1402 phase II trial in chemotherapy-induced anemia 3
(Date:2/5/2015)... -- New Market Research Reports Title Global ... 2020 has Been Added to GrandViewReseach.com Report Database ... reach USD 5.10 billion by 2020, according to a ... help identify the site of tissue damage in case ... in medical imaging applications. They have been extensively used ...
(Date:2/5/2015)... Calif. , Jan. 30, 2015  It is ... great power and potential for genomic science as a ... in disease prevention and treatment.  I was honored to ... new, government-funded precision medicine program. Since ... the science of genomics—from the first sequenced genome of ...
(Date:1/22/2015)... S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased to inform its ... of Washington,s Department of Licensing, in the United ... system for driver,s licenses and identification cards to its subsidiary, ... will start in January 2015, with enrollment and card production ...
Breaking Biology News(10 mins):IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2Valid USA Signs Contract For Washington Driver's License Issuance 2
... Engineering (NCE) at NJIT has been selected by the National ... and colleges across the nation in a new five-year program ... selection is the culmination of a two-year long effort led ... Currently, some 43 percent of engineering undergraduates switch ...
... Loud noise, especially repeated loud noise, is known ... the cochlea and eventually lead to deafness. In mammals ... able to re-grow the damaged hair cells and restore ... journal BMC Neuroscience shows that growth hormone ...
... Quest Diagnostics Incorporated (NYSE: DGX ), the ... today issued its annual report on U.S. worker drug ... includes its first state-by-state analysis of methamphetamine positives, based ... the general U.S. workforce from January-December 2010, revealing that ...
Cached Biology News:NSF funds NJIT's participation in program to retain engineering students 2Hawaii, Arkansas and Oklahoma Lead the Nation for Methamphetamine Use in the Workforce, Reveals Quest Diagnostics Drug Testing Index™ 2Hawaii, Arkansas and Oklahoma Lead the Nation for Methamphetamine Use in the Workforce, Reveals Quest Diagnostics Drug Testing Index™ 3Hawaii, Arkansas and Oklahoma Lead the Nation for Methamphetamine Use in the Workforce, Reveals Quest Diagnostics Drug Testing Index™ 4Hawaii, Arkansas and Oklahoma Lead the Nation for Methamphetamine Use in the Workforce, Reveals Quest Diagnostics Drug Testing Index™ 5
... a microprocessor controlled, high speed filter ... exceptionally smooth operation make the Lambda ... fluorescence microscopy, ratio imaging, spectrophotometry, visual ... and accurate aperture positioning. The Lambda ...
... FL is equipped with ... measurement technologies that complement ... advanced features of Fluoroskan ... Fluoroskan Ascent FL provides ...
... an enzyme that catalyzes the hydrolysis ... maltotriose, and dextrins. The,level of a-amylase ... body is of,clinical significance in the ... diabetes; plant and microbial a-amylases are,important ...
... recently launched a custom synthesis service ... Thermos siRNA molecules are: Composed ... DNA bases overhang at the 3-terminus ... fully deprotected and ready-to-use. Simply ...
Biology Products: